The facts
The paper appeared online in the New England Journal of Medicine on 4 November and in its 5 November issue; the findings had first been presented at the ESC Congress on 30 August. [1][2]
The two double-blind, placebo-controlled phase 3 trials randomized 757 adults with severe hypertriglyceridemia to receive plozasiran 25 mg or placebo every three months for one year. [1][2][3]
At 12 months, median triglyceride levels were 79% and 81% below baseline in SHASTA-3 and SHASTA-4; the placebo-adjusted differences were 45 and 47 percentage points. [1][2][3]
In the pooled analysis, acute-pancreatitis rates were 1 per 100 patient-years with plozasiran and 5 per 100 patient-years with placebo (rate ratio 0.22; P=0.008). [1][3]
Treatment-emergent adverse events occurred in 73% of patients in both pooled groups, the journal abstract reported. [1][3]
The paper says the study was funded by Arrowhead Pharmaceuticals. [1]
Still unconfirmed
- The trials followed participants for 12 months and do not establish longer-term efficacy or safety.
- The trial results do not establish a cardiovascular-outcomes benefit or by themselves determine whether treatment guidance should change.
Sources
References support the numbered facts above. Source checks: 8 Nov 2026, 03:08 UTC.
The NEJM page itself was blocked to the page opener, but its indexed primary record exposed the complete abstract and publication history; the separate PharmNews report was opened and cross-checked. The ESC congress page confirms the results were already presented on 30 August. This article dates the new journal publication to 4 November and does not describe the results as first disclosed then.
- Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis
New England Journal of Medicine · Primary source · 4 Nov 2026
The journal page opener returned 403, but the NEJM indexed result displayed the article metadata and complete abstract, including methods, results, funding and publication history. The paper is the primary record; the access limitation is disclosed.
- Plozasiran significantly reduces triglyceride levels in patients with severe hypertriglyceridaemia
European Society of Cardiology · Primary source · 30 Aug 2026
Opened the ESC congress press release. It confirms the 30 August first presentation, 757 participants and the 79%/81% triglyceride reductions; it is not evidence that the results were first revealed on the paper date.
- 중성지방 최대 81% 낮춘 플로자시란...췌장염 발생률 5분의 1로 줄어
PharmNews · Reporting · 6 Nov 2026
Opened the Korean pharmaceutical-news report. It cites the NEJM paper, reports the trial and pooled pancreatitis details, and notes the 12-month follow-up and limits to generalization; checked its figures against the journal abstract.